Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18631675 | RAPAMYCIN RESISTANT CELLS | April 2024 | December 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18623677 | COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOF | April 2024 | March 2026 | Abandon | 24 | 3 | 0 | Yes | No |
| 18584462 | PROGRAMMABLE NUCLEASES AND METHODS OF USE | February 2024 | December 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18435757 | THREE-DIMENSIONAL MICROTISSUES WITH INTEGRATED MECHANICAL LOADING | February 2024 | June 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18294032 | METHOD FOR OBTAINING A PLATELET DERIVED SECRETOME AND USES THEREOF | January 2024 | February 2026 | Allow | 24 | 1 | 1 | Yes | No |
| 18476774 | SCAFFOLDS TO TREAT SOLID TUMOR CELLS AND ESCAPE VARIANTS | September 2023 | December 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18474821 | CARDIOGENIC MESODERM FORMATION REGULATORS | September 2023 | March 2026 | Abandon | 29 | 2 | 0 | No | No |
| 18468820 | CRYOPROTECTIVE COMPOSITIONS AND USES THEREOF | September 2023 | May 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18223865 | COHESIVE THIN LIQUIDS TO PROMOTE SAFE SWALLOWING IN DYSPHAGIC PATIENTS | July 2023 | February 2025 | Allow | 19 | 2 | 0 | No | No |
| 18223733 | EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSES | July 2023 | February 2025 | Allow | 19 | 2 | 0 | No | No |
| 18335001 | METHODS AND COMPOSITIONS FOR MANUFACTURING EXTRACELLULAR MATRIX | June 2023 | April 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18139063 | USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING | April 2023 | April 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18122180 | SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS | March 2023 | May 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18172199 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS | February 2023 | January 2026 | Abandon | 35 | 5 | 0 | No | No |
| 18161246 | CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTURE | January 2023 | September 2024 | Allow | 19 | 1 | 1 | No | No |
| 18159725 | METHOD FOR GENERATING MESODERM AND/OR ENDOTHELIAL COLONY FORMING CELL-LIKE CELLS HAVING IN VIVO BLOOD VESSEL FORMING CAPACITY | January 2023 | November 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18048303 | C3B BINDING POLYPEPTIDE | October 2022 | October 2025 | Allow | 36 | 0 | 0 | No | No |
| 17799693 | THERAPEUTIC DELIVERY OF LOCKED NUCLEIC ACID CONJUGATED ANTISENSE MIR-1 | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17881655 | COMPOSITION FOR CRYOPRESERVATION OF BOVINE REPRODUCTIVE CELLS AND CRYOPRESERVATION METHOD THEREOF | August 2022 | February 2025 | Allow | 31 | 1 | 0 | No | No |
| 17795830 | Natural Killer Cells for Treatment of Coronavirus Infection | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17863675 | HUMAN PLACENTAL TISSUE GRAFT PRODUCTS, METHODS, AND APPARATUSES | July 2022 | July 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17789252 | METHOD FOR PROMOTING EXPANSION OF HEMATOPOIETIC STEM CELLS AND AGENT FOR USE IN THE METHOD | June 2022 | December 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17846725 | APPARATUS AND METHOD FOR INDUCING HUMAN OOCYTE MATURATION IN VITRO | June 2022 | June 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17787616 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND SEQUELAE THEREOF | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17784700 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | June 2022 | January 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17784408 | Cell | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17832511 | LOW OXYGEN TENSION ENHANCES ENDOTHELIAL FATE OF HUMAN PLURIPOTENT STEM CELLS | June 2022 | October 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17828393 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS | May 2022 | December 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17827357 | ORGAN MODELS | May 2022 | January 2026 | Allow | 43 | 3 | 0 | No | No |
| 17745774 | Medium Composition for Cryopreservation of Cell and Use Thereof | May 2022 | May 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17730729 | PLATFORM FOR THE INDUCTION & MAINTENANCE OF GROUND STATE PLURIPOTENCY | April 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17712732 | METHOD FOR FREEZE-DRYING CELLS IN A HYDROGEL COMPRISING NANOFIBRILLAR CELLULOSE AND FREEZE-DRIED CELLS IN AN AEROGEL COMPRISING NANOFIBRILLAR CELLULOSE | April 2022 | February 2024 | Allow | 22 | 1 | 1 | No | No |
| 17689745 | DELIVERY OF MATERIALS TO ANUCLEATE CELLS | March 2022 | June 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17653185 | METHOD FOR INDUCING DIFFERENTIATION OF ALVEOLAR EPITHELIAL CELLS | March 2022 | January 2025 | Abandon | 35 | 2 | 0 | Yes | No |
| 17639881 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | March 2022 | March 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17633871 | AGENT FOR TREATING OR PREVENTING VASCULAR DEMENTIA | February 2022 | December 2025 | Allow | 46 | 2 | 0 | No | No |
| 17632064 | NUCLEIC ACID-CALCIUM PHOSPHATE NANOPARTICLE COMPLEXES AND APPLICATION THEREOF IN BIOMINERALIZATION | February 2022 | August 2025 | Allow | 60 | 1 | 1 | No | No |
| 17584932 | Use of Engineered Renal Tissues in Assays | January 2022 | January 2024 | Allow | 23 | 1 | 0 | No | No |
| 17553509 | KITS AND METHODS FOR PREPARING PATHOGEN-INACTIVATED PLATELET COMPOSITIONS | December 2021 | April 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17543614 | PROKARYOTE-BASED CELL-FREE SYSTEM FOR THE SYNTHESIS OF GLYCOPROTEINS | December 2021 | February 2026 | Abandon | 51 | 3 | 1 | No | Yes |
| 17614333 | APPLICATION OF FLAVIN-CONTAINING MONOOXYGENASE 2 (FMO2) IN PREPARING DRUG FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | November 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17608691 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | November 2021 | October 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17516027 | PROGRAMMABLE NUCLEASES AND METHODS OF USE | November 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17606408 | A NOVEL CHROMATIN-OPENING ELEMENT FOR STABLE LONG TERM GENE EXPRESSION | October 2021 | January 2026 | Allow | 50 | 1 | 1 | Yes | No |
| 17604572 | GENE THERAPIES FOR USHER SYNDROME (USH1B) | October 2021 | April 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17603204 | SIRT1-SARNA COMPOSITIONS AND METHODS OF USE | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17602348 | GM3 SYNTHASE VECTORS AND USES THEREOF | October 2021 | October 2025 | Allow | 48 | 1 | 1 | No | No |
| 17491862 | METHODS FOR TISSUE FABRICATION | October 2021 | February 2024 | Allow | 28 | 1 | 0 | No | No |
| 17486039 | Polynucleotides, Compositions, and Methods for Polypeptide Expression | September 2021 | November 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17419154 | THERAPEUTIC AND PROPHYLACTIC AGENT FOR GLIOMA, BRAIN TUMOR MALIGNANCY MARKER, BRAIN TUMOR PROGNOSTIC MARKER, METHOD FOR DETERMINING MALIGNANCY AND PROGNOSIS OF BRAIN TUMOR AND ANTIBODY INHIBITING TUMOR PROLIFERATION | September 2021 | November 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17436920 | Methods for Cancer Diagnosis, Prognosis or Treatment | September 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17436419 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF RETINOPATHIES | September 2021 | May 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17461639 | IN VITRO NEPHROTOXICITY SCREENING ASSAY | August 2021 | January 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17431937 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATMENT OF GRN-ASSOCIATED ADULT-ONSET NEURODEGENERATION | August 2021 | May 2025 | Allow | 45 | 1 | 1 | No | No |
| 17431146 | TREATMENT OF CILIOPATHIES | August 2021 | October 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17423059 | ADVANCED CHIMERIC ANTIGEN RECEPTOR VECTORS FOR TARGETING SOLID TUMORS | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17375032 | METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS | July 2021 | January 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17362008 | COMPOSITIONS AND METHODS RELATING TO BONE REPAIR AND REGENERATION | June 2021 | March 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17361039 | ARRAY OF MICROMOLDED STRUCTURES FOR SORTING ADHERENT CELLS | June 2021 | October 2023 | Allow | 28 | 1 | 0 | No | No |
| 17350102 | Compositions and Methods of Use of Novel Strains of Lactobacillus Fermentum | June 2021 | November 2023 | Allow | 29 | 1 | 1 | No | No |
| 17348218 | BROWN FAT CELL COMPOSITIONS AND METHODS | June 2021 | October 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17329368 | COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17290571 | USE OF MRNA ENCODING OX40L TO TREAT CANCER IN HUMAN PATIENTS | April 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17261825 | CIRCULARIZED ENGINEERED RNA AND METHODS | January 2021 | February 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17148190 | METHOD OF CULTURING EUKARYOTIC CELLS | January 2021 | November 2023 | Allow | 34 | 1 | 0 | No | No |
| 17259661 | METHODS OF TREATING NON-SYNDROMIC SENSORINEURAL HEARING LOSS | January 2021 | October 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17138503 | WHOLE BLOOD SEPARATION SAMPLING APPARATUS | December 2020 | November 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17118208 | CORN BLENDS THAT INCLUDE HIGH OIL CORN AND METHODS OF MAKING ONE OR MORE BIOCHEMICALS USING HIGH OIL CORN OR CORN BLENDS THAT INCLUDE HIGH OIL CORN | December 2020 | March 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17104094 | CELL CULTURE METHOD, PRODUCT PRODUCING METHOD, AND CELL CULTURE DEVICE | November 2020 | December 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 17056648 | MICROENCAPSULATED MODIFIED POLYNUCLEOTIDE COMPOSITIONS AND METHODS | November 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17080166 | CRYOPROTECTIVE COMPOSITIONS AND USES THEREOF | October 2020 | October 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17049782 | RAPAMYCIN RESISTANT CELLS | October 2020 | February 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17039507 | CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT | September 2020 | September 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17023011 | METHOD OF SEPARATING VESICLE FROM SAMPLE | September 2020 | October 2024 | Abandon | 49 | 2 | 1 | No | No |
| 17021621 | USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING | September 2020 | January 2023 | Allow | 28 | 0 | 0 | Yes | No |
| 17015443 | ORGAN CONTAINER WITH OXYGENATION OPTION | September 2020 | March 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17013389 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW | September 2020 | June 2021 | Allow | 9 | 2 | 0 | Yes | No |
| 17007984 | METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATIONS AND METHODS OF USE | August 2020 | October 2024 | Abandon | 50 | 2 | 0 | No | No |
| 16964739 | METHODS AND SYSTEM OF HUMAN HEMOGENIC REPROGRAMING | July 2020 | January 2024 | Abandon | 41 | 0 | 1 | No | No |
| 16960816 | CELL CULTURING METHOD AND DEVICE | July 2020 | November 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16912391 | Method for Assessing a Compound Interacting with a Target on Epithelial Cells | June 2020 | January 2022 | Abandon | 19 | 2 | 0 | No | No |
| 16882099 | METHODS OF GENERATING ENUCLEATED ERYTHROID CELLS | May 2020 | June 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16881932 | METHOD FOR VISUALIZING NEURONS | May 2020 | March 2023 | Allow | 34 | 1 | 0 | No | No |
| 16874275 | MEDIA COMPOSITIONS FOR NEURONAL CELL CULTURE | May 2020 | May 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16762447 | METHODS OF PREPARING HEMATOPOIETIC PROGENITOR CELLS IN VITRO | May 2020 | March 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16760780 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | April 2020 | February 2023 | Allow | 34 | 0 | 1 | Yes | No |
| 16860894 | COMPOSITIONS AND METHODS FOR STORING LIQUID BIOSPECIMENS | April 2020 | March 2024 | Allow | 46 | 4 | 0 | Yes | No |
| 16759642 | Kidney Organoids and Methods of Manufacturing | April 2020 | August 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16759671 | AUGMENTATION OF FERTILITY BY PLATELET RICH PLASMA | April 2020 | January 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16846642 | ADHERENT CELL CULTURE METHOD | April 2020 | December 2024 | Abandon | 56 | 4 | 1 | No | No |
| 16834235 | MICROFLUIDIC DEVICES AND METHODS OF DESIGNING AND USING MICROFLUIDIC DEVICES | March 2020 | October 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16834952 | COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOF | March 2020 | December 2023 | Allow | 44 | 2 | 1 | Yes | No |
| 16828698 | MAMMALIAN CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | March 2020 | June 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16650168 | IN VITRO MATURATION CULTURE MEDIUM OF IMMATURE OOCYTES AND USE THEREOF | March 2020 | July 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16814021 | SELECTIVE ENRICHMENT MEDIA AND USES THEREOF | March 2020 | March 2023 | Allow | 37 | 2 | 1 | No | No |
| 16643710 | Cell Aggregate Including Retinal Tissue and Production Method Therefor | March 2020 | February 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16790286 | COHESIVE THIN LIQUIDS TO PROMOTE SAFE SWALLOWING IN DYSPHAGIC PATIENTS | February 2020 | September 2023 | Allow | 43 | 3 | 1 | No | No |
| 16638801 | METHOD FOR CULTURING 3-DIMENSIONAL LUNG CANCER ORGANOID AND METHOD FOR PREPARING PATIENT-DERIVED XENOGRAFT ANIMAL MODEL USING SAME | February 2020 | September 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16638918 | CARDIOGENIC MESODERM FORMATION REGULATORS | February 2020 | June 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16638544 | THREE-DIMENSIONAL MICROTISSUES WITH INTEGRATED MECHANICAL LOADING | February 2020 | November 2023 | Allow | 45 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CORDAS, EMILY ANN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CORDAS, EMILY ANN works in Art Unit 1632 and has examined 276 patent applications in our dataset. With an allowance rate of 55.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner CORDAS, EMILY ANN's allowance rate of 55.8% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CORDAS, EMILY ANN receive 2.90 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CORDAS, EMILY ANN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +58.8% benefit to allowance rate for applications examined by CORDAS, EMILY ANN. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.4% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.5% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 33.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 32% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 94.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.